Pioneering Intravitreal Gene Therapy for Wet AMD: 7 Years of Clinical Experience from Phase 1 to Phase 3

Time: 11:30 am
day: Conference Day One

Details:

• Examining key learnings from early-stage intravitreal gene therapy studies and how these learnings impacted late-stage study design
• Highlighting key efficacy and safety data from the phase 1 OPTIC and phase 2 LUNA studies
• Exploring an end-to-end journey of one of the first patients dosed with Ixo-vec  

Speakers:

Adam Turpcu Adam Turpcu serves as Senior Vice President of Clinical Development at Adverum Biotechnologies, where he has contributed for six years to advancing gene therapy for Read more